Department of Molecular Medicine & Pathology, University of Auckland, Auckland, New Zealand.
Maurice Wilkins Centre for Molecular Biodiscovery, New Zealand, Auckland.
Expert Rev Vaccines. 2023 Jan-Dec;22(1):885-899. doi: 10.1080/14760584.2023.2268724. Epub 2023 Oct 17.
The unique mucosal immune system allows the generation of robust protective immune responses at the front line of pathogen encounters. The needle-free delivery route and cold chain-free logistic requirements also provide additional advantages in ease and economy. However, the development of mucosal vaccines faces several challenges, and only a handful of mucosal vaccines are currently licensed. These vaccines are all in the form of live attenuated or inactivated whole organisms, whereas no subunit-based mucosal vaccine is available.
The selection of antigen, delivery vehicle, route and adjuvants for mucosal vaccination are highly important. This is particularly crucial for subunit vaccines, as they often fail to elicit strong immune responses. Emerging research is providing new insights into the biological and immunological uniqueness of mucosal tissues. However, many aspects of the mucosal immunology still await to be investigated.
This article provides an overview of the current understanding of mucosal vaccination and discusses the remaining knowledge gaps. We emphasize that because of the potential benefits mucosal vaccines can bring from the biomedical, social and economic standpoints, the unmet goal to achieve mucosal vaccine success is worth the effort.
独特的黏膜免疫系统允许在病原体接触的第一线产生强大的保护性免疫反应。无针输送途径和无需冷链物流的要求也在简便性和经济性方面提供了额外的优势。然而,黏膜疫苗的开发面临着若干挑战,目前仅有少数黏膜疫苗获得许可。这些疫苗均采用减毒活或失活的全生物体形式,而尚无基于亚单位的黏膜疫苗。
黏膜疫苗接种的抗原、输送载体、途径和佐剂的选择非常重要。对于亚单位疫苗而言尤其如此,因为它们通常无法引发强烈的免疫反应。新兴研究为黏膜组织的生物学和免疫学独特性提供了新的见解。然而,黏膜免疫学的许多方面仍有待研究。
本文概述了目前对黏膜疫苗接种的理解,并讨论了尚存的知识空白。我们强调,由于黏膜疫苗从生物医学、社会和经济角度来看具有潜在的益处,因此实现黏膜疫苗成功的未竟目标是值得努力的。